Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat versus placebo in ambulant adults with Becker muscular dystrophy
NL-OMON50228Phase 2Active, not recruiting
- Sponsor
- Italfarmaco
- Start
- Feb 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Becker muscular dystrophy (BMD) comparing Givinostat with Placebo (2 arms). Primary endpoint: Mean change in total fibrosis. Started Feb 2019; status: active, not recruiting.
02
Drugs
givinostat
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NL-OMON50228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50228.